Of the many varied approaches to mimic some of the beneficial metabolic response to calorie restriction, mTOR inhibition is arguably the most well studied. Countless animal studies have been conducted, and early clinical trials for novel mTOR inhibitors have taken place. The mTOR inhibitor rapamycin is a generic, low cost drug now used by a growing number of people for its potential to slow aging. That potential remains to be proven in humans, but in mice rapamycin produces a reliable 10% to 20% increase in life span. Like calorie restriction, mTOR inhibitors appear to produce their benefits as a consequence of the increased operation or efficiency of autophagy, a collection of maintenance processes that recycle damaged proteins and structures in the cell. Near all forms of stress response converge on autophagy, which acts to improve cell function and resilience.
Today's open access review is a short deep dive into the biochemistry of mTOR, the role of mTOR in aging, and ability of mTOR inhibitors to modestly slow aging. If there is a single point that the authors would like you to take away with you, it is that mTOR is not a straightforward target. Optimal mTOR inhibition is context and tissue dependent, and there is probably room to improve on the sort of pharmacological mTOR inhibition conducted to date via rapamycin and similar small molecule drugs. Nonetheless, there is still a compelling argument to be made that rapamcyin is a cost-effective treatment for aging, blunt as it is, and modest as the effects are. A small benefit for a trivial cost is still a win. That argument still needs to be resolved with human data, however, and movement towards that goal is painfully slow. Low cost drugs have few champions willing to underwrite the huge expense of formal human trials.
mTOR signaling in aging: from causality to geroprotective interventions and hallmark-level outcomes
Protein kinases are tightly regulated enzymes that ensure signaling fidelity through precise spatial and temporal control of their activity. Protein kinases constitute one of the largest and most functionally important enzyme families. They regulate virtually all major biological processes by transferring phosphate groups from adenosine triphosphate (ATP) to serine, threonine, or tyrosine residues. This reversible post-translational modification propagates intracellular signaling through phosphorylation cascades, whereas phosphatases terminate signaling by removing phosphate groups from target proteins.
Among phosphatidylinositol 3-kinase-related kinases (PIKKs), mechanistic target of rapamycin (mTOR) occupies a central position in aging biology owing to its role in coordinating nutrient sensing, metabolism, and stress adaptation. mTOR is a multidomain serine/threonine kinase that integrates environmental and intracellular signals to regulate metabolism, growth, autophagy, and cell survival. It assembles into two functionally distinct complexes, mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2), which differ in molecular composition, upstream regulation, and downstream signaling outputs.
Rather than functioning as a linear signaling pathway, mTOR acts as a dynamic signaling hub that coordinates anabolic and catabolic processes in response to nutrient availability, energy status, and cellular stress. Dysregulated or persistent mTOR activation is associated with reduced metabolic flexibility, impaired stress adaptation, and accelerated aging, whereas context-dependent modulation of mTORC1 and mTORC2 supports cellular homeostasis and organismal resilience. Consequently, mTOR has become one of the principal molecular targets in geroscience and a promising focus for interventions aimed at promoting healthy aging.
This review provides an integrative analysis of the molecular architecture and biological functions of mTOR signaling, with particular emphasis on the emerging role of mTORC2 in aging and longevity. It examines mechanistic, genetic, experimental, and translational evidence linking mTOR signaling to lifespan regulation and critically evaluates current geroprotective interventions that modulate this pathway. Finally, the review discusses the therapeutic opportunities, biological trade-offs, and remaining translational challenges of targeting mTOR signaling to improve healthspan and healthy aging.
View the full article at FightAging
